Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
Direxion Daily S&P Biotech Bull 3X Shares (LABU): Leveraged Exposure to the Biotech Sector

Direxion Daily S&P Biotech Bull 3X Shares (LABU): Leveraged Exposure to the Biotech Sector

Key Takeaways

  • LABU is a leveraged exchange-traded fund (ETF) that seeks daily investment results equal to 300% of the performance of the S&P Biotechnology Select Industry Index.
  • It is issued by Direxion and was launched on May 28, 2015, with a net expense ratio of approximately 0.96%.
  • The fund is designed for sophisticated, short-term traders seeking amplified exposure to U.S. biotechnology stocks, not for buy-and-hold investors.
  • Because it resets leverage daily, its returns over periods longer than one day can differ significantly from three times the index’s cumulative return.
  • LABU carries very high volatility and substantial risk of loss, particularly during extended market declines.

Introduction

The Direxion Daily S&P Biotech Bull 3X Shares, trading under the ticker LABU, is a leveraged exchange-traded fund (ETF) that aims to deliver three times the daily performance of the S&P Biotechnology Select Industry Index. An ETF is a fund that trades on an exchange like a stock and holds a basket of assets. LABU stands out because of its aggressive, amplified exposure to one of the most volatile corners of the health care sector: biotechnology. Investors follow it as a high-powered tool for expressing short-term views on biotech stocks, but its leverage makes it unsuitable for many long-term portfolios. I also checked this using Tickeron’s AI Screener to see how the fund compares to others in the industry.

ETF Overview and Investment Strategy

LABU’s investment objective is straightforward but demanding: it seeks daily investment results, before fees and expenses, of 300% of the performance of the S&P Biotechnology Select Industry Index. To achieve this amplified exposure, the fund invests at least 80% of its assets in the securities that make up the underlying index and in financial instruments—most notably swap agreements—that provide leveraged exposure to that index. Swaps are contracts through which the fund can gain or lose exposure to the index’s returns without holding every underlying stock directly.

The fund is passively managed, meaning it tracks a rules-based index rather than relying on a portfolio manager’s stock selection. The S&P Biotechnology Select Industry Index is an equal-weighted benchmark composed of U.S.-listed biotechnology companies, spanning established names and smaller, clinical-stage developers alike. LABU is issued by Direxion, a firm known for its lineup of leveraged and inverse ETFs, and was launched on May 28, 2015.

Portfolio Holdings and Sector Exposure

LABU’s sector exposure is concentrated entirely within biotechnology and, more broadly, the health care industry. Its portfolio holdings typically include a large number of underlying biotech equities—often well over 100 names—alongside the swap contracts and short-term cash instruments used to generate the fund’s 3x leverage. Because the index is equal-weighted, no single stock dominates the portfolio; top underlying equity positions have historically included companies such as MRNA, REGN, VRTX, INSM, and NTRA, though these individual weights are generally modest.

The fund’s expense ratio—the annual fee deducted from fund assets—is approximately 0.96%, which is higher than typical unleveraged index ETFs and reflects the cost of maintaining the derivative exposure. Because the fund rebalances and resets its leverage daily, its composition and the mechanics of its swaps are adjusted continuously to keep the 300% target in place.

Why Investors Follow LABU

LABU attracts attention primarily as a vehicle for amplified, short-term bets on biotechnology. The biotech sector is known for sharp price swings driven by clinical trial results, regulatory decisions from the U.S. Food and Drug Administration (FDA), mergers and acquisitions (M&A), and broader risk sentiment toward high-growth health care names. LABU allows traders to magnify these moves—both upward and downward—on a daily basis without using a margin account or trading individual stocks.

For experienced traders, the fund offers a convenient way to gain concentrated leverage on a diversified basket of biotech companies in a single, liquid ticker. It can also serve as a tactical portfolio tool for expressing a short-term bullish view on the sector. However, its design makes it a poor fit for investors seeking long-term growth or steady income, since the daily reset mechanism causes its long-run returns to diverge meaningfully from a simple 3x multiple of the index.

Risks and Important Considerations

LABU’s most significant risk is leverage combined with daily reset. While it targets 300% of the index’s return each day, compounding means its performance over weeks, months, or years can be drastically different from three times the index’s cumulative return—often to the downside in volatile or declining markets. This effect, sometimes called volatility decay, can erode value even when the underlying index is roughly flat.

Additional risks include sector concentration in biotechnology, which is inherently volatile and sensitive to clinical, regulatory, and funding developments; tracking error, or the gap between the fund’s actual performance and its stated objective; and the fund’s relatively high expense ratio. Leveraged ETFs are also generally intended to be held for no more than a single trading session, and holding them longer can produce outcomes that differ substantially from investor expectations. These characteristics make LABU suitable only for sophisticated traders who understand and actively monitor leveraged products.

Using AI Tools in My Research

When analyzing leveraged products like this, I often rely on Tickeron’s AI Screener. It is an AI-powered stock and ETF discovery platform that helps traders and investors identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. Users can efficiently screen thousands of stocks and ETFs to surface ideas that match their own investment strategies. Explore the AI Screener to build a watchlist tailored to your approach.

Conclusion

The Direxion Daily S&P Biotech Bull 3X Shares (LABU) occupies a distinctive niche in the ETF landscape: it offers aggressive, daily-reset leverage over the U.S. biotechnology sector in a single, liquid package. Its investment strategy and financial profile make it a powerful tactical instrument for experienced traders, while its concentration, leverage, and volatility risk make it unsuitable for most long-term investors. Understanding how its daily 3x objective works is essential before considering any position.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: LABU

Contributor

My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.


Momentum Indicator for LABU turns negative, indicating new downward trend

LABU saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 94 similar instances where the indicator turned negative. In 90 of the 94 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for LABU turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 49 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

LABU moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LABU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for LABU entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +17.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where LABU advanced for three days, in 293 of 310 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

LABU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Notable companies

The most notable companies in this group are ABBVIE (NYSE:ABBV), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX).

Industry description

The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the S&P Biotechnology Select Industry Index ("index"). The fund, under normal circumstances, invests at least 80% of its net assets in financial instruments, such as swap agreements, securities of the index, and ETFs that track the index, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards ("GICS"). The fund is non-diversified.

Market Cap

The average market capitalization across the Direxion Daily S&P Biotech Bull 3X ETF (LABU) ETF is 14.39B. The market cap for tickers in the group ranges from 136.65M to 514.78B. ABBV holds the highest valuation in this group at 514.78B. The lowest valued company is CMPX at 136.65M.

High and low price notable news

The average weekly price growth across all stocks in the Direxion Daily S&P Biotech Bull 3X ETF (LABU) ETF was 84%. For the same ETF, the average monthly price growth was 74%, and the average quarterly price growth was 334%. SLS experienced the highest price growth at 113%, while CADL experienced the biggest fall at -42%.

Volume

The average weekly volume growth across all stocks in the Direxion Daily S&P Biotech Bull 3X ETF (LABU) ETF was 30%. For the same stocks of the ETF, the average monthly volume growth was 22% and the average quarterly volume growth was -6%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 45
Price Growth Rating: 57
SMR Rating: 87
Profit Risk Rating: 81
Seasonality Score: 15 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
CBRS fell -6.07% to $97.86 in the opening minutes of Wednesday's regular session, down from Tuesday's close of $104.18 — the move occurred during market hours, not premarket or after-hours. No verified news or fundamental catalyst found: no new filing, contract, or analyst action explains the drop, which is likely continued give-back from the post-earnings pop and the stock's habitual volatility — CBRS has averaged a ±4.5% daily swing over the past 60 sessions, and 17 of those sessions moved as much or more.
NVIDIA reported revenue of $115.84 billion for the third quarter of fiscal 2027, up 103% year over year and ahead of both company guidance and consensus estimates. Non-GAAP earnings per share (EPS, a measure of profit per outstanding share) came in at $2.68 , beating the roughly $2.47 analysts had expected.